Merck Outlines Plans For 2009 NDA Filings; Migraine Drug Is Best Bet

Merck's fledgling bioventures business may have dominated headlines following the company's recent analyst day, but the firm's other initiatives are likely to contribute more to near-term growth as Merck tries to address the revenue gap that will be left by key patent expirations in the next few years